The invention relates to a water-soluble fermented pea extract. The invention also relates to a process for the preparation thereof and to the use thereof in the human and animal nutrition industry as well as in the pharmaceutical, nutraceutical and cosmetics industries.

The invention relates to a water-soluble fermented pea extract. The invention also relates to a process for the preparation thereof and to the use thereof in the human and animal nutrition industry as well as in the pharmaceutical, nutraceutical and cosmetics industries.

The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.

In one aspect, the present disclosure provides compounds of the formula (I): wherein the variables are as defined herein. In another aspect, the present disclosure provides compounds of the formula (V): wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure provides antibody drug conjugates comprising compounds of the present disclosure. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds and anti-body drug conjugates disclosed herein. ##STR00001##

A process of preparing sugarless peptide cultivated enzyme is provided in which surfaces of vegetable and fruit are cleaned and sterilized by hyperbaric oxygen, the vegetable and fruit with flesh and skin are smashed to a vegetable and fruit paste having dregs, the dregs is separated from the vegetable and fruit paste which is then soaked to form a raw vegetable and fruit solution which is poured into a fermentation tank including a catalase peptide ceramic layer having graphene, the raw vegetable and fruit solution cyclically flows through the catalase peptide ceramic layer for 1.5 months to 3 months of fermentation and cultivation period, and the cultivated vegetable and fruit solution is filtered to obtain a liquid sugarless vegetable and fruit enzyme product.

A process of preparing sugarless peptide cultivated enzyme is provided in which surfaces of vegetable and fruit are cleaned and sterilized by hyperbaric oxygen, the vegetable and fruit with flesh and skin are smashed to a vegetable and fruit paste having dregs, the dregs is separated from the vegetable and fruit paste which is then soaked to form a raw vegetable and fruit solution which is poured into a fermentation tank including a catalase peptide ceramic layer having graphene, the raw vegetable and fruit solution cyclically flows through the catalase peptide ceramic layer for 1.5 months to 3 months of fermentation and cultivation period, and the cultivated vegetable and fruit solution is filtered to obtain a liquid sugarless vegetable and fruit enzyme product.

A method of screening is provided. In certain embodiments, the method involves a) obtaining the nucleotide sequences of: i. a heavy chain-encoding nucleic acid that encodes the variable domain of a heavy chain of a first antibody of an animal; and ii. a light chain-encoding nucleic acid that encodes the variable domain of a light chain of the first antibody; b) obtaining nucleotide sequences of cDNAs encoding at least a portion of the antibody repertoire of the animal; c) computationally screening the sequences obtained in b) to identify heavy and light chain sequences that are related by lineage to the heavy and light chain sequences of a); and d) testing at least one pair of the heavy and light chain sequences identified in c) to identify a second antibody that binds to the same antigen as the first antibody.

The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.

Disclosed are components and systems for cell-free glycoprotein synthesis (CFGpS). In particular, the components and systems include and utilize prokaryotic cell lysates from engineered prokaryotic cell strains that have been engineered to enable cell-free synthesis of glycoproteins.

Described are compositions comprising α-galactosidase A enzymes with unique carbohydrate profiles, as well as methods for manufacturing and purifying such enzymes. Also described methods of treating, preventing, and/or ameliorating Fabry Disease by administering such enzymes to a subject in need thereof. Also described are compositions comprising migalastat in combination with such α-galactosidase A enzymes.